LENZ Q4 2025 prelim product rev $1.6M; >20K prescriptions for VIZZ launch

LENZ Therapeutics, Inc.

2025-FY EPS reported -$2.85 vs consensus -$0.99 ▼ miss (-187.7%)

Net product revenue of ~$1.6M from VIZZ in first launch quarter (Q4 2025), with over 20,000 prescriptions filled.
Over 6,500 unique eye care professionals prescribed VIZZ; more than 55% prescribed multiple times in Q4.
VIZZ launched October 2025; broad retail and epharmacy access achieved by mid-November 2025.
Announced fourth international commercialization partnership with Lunatus for Middle East with milestones and revenue share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.